PolyPid Ltd. (NASDAQ:PYPD) Short Interest Update

PolyPid Ltd. (NASDAQ:PYPD) saw a large decrease in short interest in January. As of January 15th, there was short interest totaling 19,282 shares, a decrease of 71.7% from the December 31st total of 68,118 shares. Currently, 0.2% of the shares of the company are sold short. Based on an average daily trading volume, of 85,748 shares, the days-to-cover ratio is presently 0.2 days. Based on an average daily trading volume, of 85,748 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.2% of the shares of the company are sold short.

Analysts Set New Price Targets

PYPD has been the topic of several recent research reports. Weiss Ratings restated a “sell (d-)” rating on shares of PolyPid in a research report on Monday, December 29th. Wall Street Zen raised PolyPid from a “sell” rating to a “hold” rating in a report on Sunday, November 16th. Roth Mkm cut their target price on PolyPid from $10.00 to $9.00 and set a “buy” rating for the company in a research note on Thursday, November 13th. Finally, Citigroup reiterated a “market outperform” rating on shares of PolyPid in a research report on Monday, December 1st. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $12.25.

PolyPid Trading Down 0.2%

Shares of PolyPid stock traded down $0.01 on Thursday, hitting $4.71. 21,951 shares of the company traded hands, compared to its average volume of 83,176. PolyPid has a 12-month low of $2.30 and a 12-month high of $5.05. The company has a market cap of $74.89 million, a P/E ratio of -1.58 and a beta of 1.51. The firm’s 50-day simple moving average is $4.19 and its 200 day simple moving average is $3.73.

PolyPid (NASDAQ:PYPD) last released its earnings results on Wednesday, November 12th. The company reported ($0.37) EPS for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.17. Analysts predict that PolyPid will post -1.79 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. BNP Paribas Financial Markets lifted its holdings in shares of PolyPid by 56.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 9,734 shares of the company’s stock worth $32,000 after acquiring an additional 3,500 shares during the last quarter. Lumbard & Kellner LLC bought a new stake in PolyPid in the second quarter valued at approximately $135,000. Finally, AIGH Capital Management LLC increased its stake in shares of PolyPid by 27.0% in the second quarter. AIGH Capital Management LLC now owns 1,194,108 shares of the company’s stock worth $4,215,000 after buying an additional 253,727 shares during the period. 26.47% of the stock is owned by hedge funds and other institutional investors.

About PolyPid

PolyPid Ltd is a clinical?stage biotechnology company focused on polymer?based drug delivery technologies designed to enhance the performance of therapeutic agents at mucosal surfaces. Leveraging its proprietary Mucoadhesive & Mucus?Penetrating (MMP) platform, PolyPid develops long?acting formulations for ocular, oral and pulmonary indications. Its lead candidates include OncoTears and OralTear, therapies targeting dry eye and dry mouth conditions, respectively, as well as Paclical, a polymer?formulated paclitaxel designed to improve tolerability and antitumor activity in oncology patients.

Founded in 2003 and headquartered in Jerusalem, Israel, PolyPid has assembled an international patent portfolio covering key markets in North America, Europe and Asia.